The city of Mesquite, Texas, currently has 4 active clinical trials seeking participants for Rheumatoid Arthritis research studies.
A Study of Baricitinib in Participants With Rheumatoid Arthritis
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Southwest Rheumatology, P.A., Mesquite, Texas
Conditions: Rheumatoid Arthritis
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
Recruiting
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with moderate to severe rheumatoid arthritis who have failed prior therapies. Participants will be given imvotamab or placebo through a vein (i.e., intravenously). A placebo is a look-alike substance that contains no active drug
Gender:
All
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: Southwest Rheumatology Research, Mesquite, Texas
Conditions: Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
Splenic Stimulation for RA
Recruiting
This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and accessories. The study will consist of 4 study periods, including a Randomized Control Trial period (Period 1), an Open Label period (Period 2), a Treat-to-target period (Period 3), and a Long-term Follow-up period (Period 4). Participants eligible for implant will have active r... Read More
Gender:
All
Ages:
Between 22 years and 75 years
Trial Updated:
02/12/2024
Locations: Southwest Rheumatology Research, Mesquite, Texas
Conditions: Rheumatoid Arthritis
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis (RENOIR)
Recruiting
RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe Rheumatoid Arthritis (RA)
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/11/2023
Locations: AnaptysBio Investigative Site 10-108, Mesquite, Texas
Conditions: Rheumatoid Arthritis